Download PDF
Frauenheilkunde up2date 2015; 9(2): 133-151
DOI: 10.1055/s-0033-1358114
Gynäkologische Endokrinologie und Reproduktionsmedizin
Georg Thieme Verlag KG Stuttgart · New York

Kinderwunsch und Multiple Sklerose[*]

Sandra Herbstritt
,
Ralf Gold
,
Kerstin Hellwig
Further Information

Publication History

Publication Date:
21 April 2015 (online)

Also available at
    Permissions and Reprints All articles of this category

See also:

Kinderwunsch und Multiple SkleroseAktuelle Neurologie 2014; 41(08): 476-490
DOI: 10.1055/s-0034-1387219

Kernaussagen

Multiple Sklerose und Kinderwunsch schließen sich im Allgemeinen nicht aus. Negative Effekte auf die Erkrankung sind generell nicht zu erwarten. Der Vergleich mit gesunden Kontrollgruppen aus großen Datenbanken ergab auch einen weitgehend von der MS unabhängigen Schwangerschaftsverlauf aus gynäkologischer Sicht [97].

Wissenschaftler weltweit beschäftigen sich zunehmend mit diesem Themengebiet, sodass in den letzten beiden Jahren weitere Sicherheitsdaten zu Medikamenten (insbesondere Interferonen, zum kleinen Teil auch Natalizumab, Fingolimod, DMF und auch Teriflunomid) veröffentlicht wurden. Informationen finden sich auch in den Leitlinien des Kompetenznetzes Multiple Sklerose (KKNMS) (http://www.kompetenznetze-medizin.de/Netzwerke/NeurologischeErkrankungen/MultipleSklerose.aspx).

Um die schon bestehende Infrastruktur des Registers auch weiterhin zu nutzen, möchten wir mit diesem Artikel auf unser Schwangerschaftsregister hinweisen. Hierfür sind alle Schwangeren mit klinisch isoliertem Syndrom, MS oder auch NMO geeignet oder Frauen mit diesen Erkrankungen und kurzfristigem Kinderwunsch sowie Frauen mit MS und unerfülltem Kinderwunsch. Gerne können Sie sich selbst oder die Patientinnen am besten per E-Mail (k.hellwig@klinikum-bochum.de) an uns wenden.

Weitere Informationen sind auch auf der Internetseite des Registers: www.ms-und-kinderwunsch.de zu finden.

* Mod. nach Erstpublikation in Akt Neurol 2014; 41: 476–490


 

  • Literatur

  • 1 Orton SM, Herrera BM, Yee IM et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006; 5: 932-936
    CrossrefGoogle Scholar
  • 2 Cavalla P, Rovei V, Masera S et al. Fertility in patients with multiple sclerosis: current knowledge and future perspectives. Neurol Sci 2006; 27: 231-239
    CrossrefPubMedGoogle Scholar
  • 3 Jalkanen A, Alanen A, Airas L. Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler 2010; 16: 950-955
    CrossrefGoogle Scholar
  • 4 Thöne J, Kollar S, Nousome D et al. Serum anti-Müllerian hormone levels in reproductive-age women with relapsing remitting multiple sclerosis. Mult Scler 2015; 21: 41-47
    CrossrefGoogle Scholar
  • 5 Fachinformation. Betaferon® 250 Mikrogramm/ml. 2012. http://www.deutschesapothekenportal.de/fileadmin/bestellungen/fi_betaferon.pdf
    Google Scholar
  • 6 Cocco E, Sardu C, Gallo P et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008; 14: 1225-1233
    CrossrefGoogle Scholar
  • 7 Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol 2012; 72: 682-694
    CrossrefGoogle Scholar
  • 8 Laplaud DA, Leray E, Barriere P et al. Increase in multiple sclerosis relapse rate following in vitro fertilization. Neurology 2006; 66: 1280-1281
    CrossrefGoogle Scholar
  • 9 Michel L, Foucher Y, Vukusic S et al. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012; 83: 796-802
    CrossrefPubMedGoogle Scholar
  • 10 Hellwig K, Beste C, Brune N et al. Increased MS relapse rate during assisted reproduction technique. J Neurol 2008; 255: 592-593
    CrossrefGoogle Scholar
  • 11 Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol 2013; 149: 219-224
    CrossrefGoogle Scholar
  • 12 Gold SM, Mohr DC, Huitinga I et al. The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol 2005; 26: 644-652
    CrossrefGoogle Scholar
  • 13 Confavreux C, Hutchinson M, Hours MM et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998; 339: 285-291
    CrossrefGoogle Scholar
  • 14 Hellwig K, Brune N, Haghikia A et al. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. Acta Neurol Scand 2008; 118: 24-28
    CrossrefGoogle Scholar
  • 15 Park-Wyllie L, Mazzotta P, Pastuszak A et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-392
    CrossrefPubMedGoogle Scholar
  • 16 Schaefer C, Spielmann H, Vetter K, Weber-Schöndorfer C. Arzneimittel in Schwangerschaft und Stillzeit. 8. Aufl.. München: Elsevier, Urban & Fischer Verlag; 2012
    Google Scholar
  • 17 Ruffatti A, Marson P, Pengo V et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev 2007; 6: 196-202
    CrossrefGoogle Scholar
  • 18 Matok I, Levy A, Wiznitzer A et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012; 57: 699-705
    CrossrefGoogle Scholar
  • 19 Vukusic S, Hutchinson M, Hours M et al. Pregnancy In Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004; 127: 1353-1360
    CrossrefGoogle Scholar
  • 20 Koch M, Uyttenboogaart M, Heersema D et al. Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80: 676-678
    CrossrefGoogle Scholar
  • 21 DʼHooghe MB, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry 2010; 81: 38-41
    CrossrefGoogle Scholar
  • 22 Ramagopalan S, Yee I, Byrnes J et al. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2012; 83: 793-795
    CrossrefGoogle Scholar
  • 23 Airas L, Saraste M, Rinta S et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 2008; 151: 235-243
    CrossrefGoogle Scholar
  • 24 Voskuhl RR, Gold SM. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol 2012; 8: 255-263
    CrossrefGoogle Scholar
  • 25 van der Kop ML, Pearce MS, Dahlgren L et al. Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol 2011; 70: 41-50
    CrossrefGoogle Scholar
  • 26 Dahl J, Myhr KM, Daltveit AK et al. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology 2005; 65: 1961-1963
    CrossrefGoogle Scholar
  • 27 Dahl J, Myhr KM, Daltveit AK et al. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol 2008; 255: 623-627
    CrossrefGoogle Scholar
  • 28 Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology 2009; 73: 1831-1836
    CrossrefGoogle Scholar
  • 29 Lu E, Zhao Y, Zhu F et al. British Columbia Multiple Sclerosis Clinic Neurologists. Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology 2013; 80: 447-452
    CrossrefGoogle Scholar
  • 30 Pastò L, Portaccio E, Ghezzi A et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol 2012; 12: 165
    CrossrefGoogle Scholar
  • 31 Borisow N, Döring A, Pfueller CF et al. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J 2012; 3: 9
    CrossrefGoogle Scholar
  • 32 Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol 2013; 260: 1202-1214
    CrossrefGoogle Scholar
  • 33 Geissbühler YBH, Hernández-Diaz S et al. Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in Multiple Sclerosis. Lyon, France: ECTRIMS; 2012. (12 Oct): Abstract 751
    Google Scholar
  • 34 Kieseier B, Benamor M, Truffinet P. Pregnancy Outcomes from the Teriflunomide Clinical Development Program Pactrims. 2013: P79.
    Google Scholar
  • 35 Briggs GG, Freeman RK, Yaffe SJ. Classification of drugs for teratogenic risk: an anachronistic way of counseling: a reply to Merlob and Stahl. Birth Defects Res A Clin Mol Teratol 2003; 67: 207-208
    CrossrefGoogle Scholar
  • 36 Lu E, Wang BW, Guimond C et al. Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review. Neurology 2012; 79: 1130-1135
    CrossrefGoogle Scholar
  • 37 Amato MP, Portaccio E, Ghezzi A et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology 2010; 75: 1794-1802
    CrossrefGoogle Scholar
  • 38 Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler 2009; 15: 1037-1042
    CrossrefPubMedGoogle Scholar
  • 39 Sandberg-Wollheim M, Frank D, Goodwin TM et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005; 65: 802-806
    CrossrefGoogle Scholar
  • 40 Sandberg-Wollheim M, Alteri E, Moraga MS et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011; 17: 423-430
    CrossrefGoogle Scholar
  • 41 Boskovic R, Wide R, Wolpin J et al. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 2005; 65: 807-811
    CrossrefGoogle Scholar
  • 42 Hellwig K, Haghikia A, Rockhoff M et al. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord 2012; 5: 247-253
    CrossrefGoogle Scholar
  • 43 Fragoso YD, Adoni T, Alves-Leon SV et al. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. CNS Drugs 2013; 27: 955-961
    CrossrefGoogle Scholar
  • 44 Coyle PK, Johnson K, Pardo L et al. Pregnancy outcomes in patients with multiple sclerosis treated with glatiramer acetate (Copaxone). Neurology 2003; 60: A60
    Google Scholar
  • 45 Giannini M, Portaccio E, Ghezzi A et al. Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol 2012; 12: 124
    CrossrefGoogle Scholar
  • 46 Ebrahimi N, Herbstritt S, Gold R et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015; 21: 198-205
    CrossrefGoogle Scholar
  • 47 Cristiano LBC, Bloomgren G. Preliminary evaluation of pregnancy outcomes from the Tysabri® (natalizumab) Pregnancy Exposure Registry. ECTRIMS 2011: P1005.
    Google Scholar
  • 48 Fagiu J, Burman J. Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand 2014; 129: e27-e29
    CrossrefGoogle Scholar
  • 49 Haghikia A, Langer Gould A, Rellensmann G et al. Natalizumab use during third trimester of pregnancy. JAMA Neurol 2014; DOI: 10.1001/jamaneurol.2014.209.
    Google Scholar
  • 50 Palmeira P, Quinello C, Silveira-Lessa AL et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012: 985646
    Google Scholar
  • 51 Fachinformation. Gilenya®. Mai 2014.
    Google Scholar
  • 52 Karlsson G, Francis G, Koren G et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014; 82: 674-680
    CrossrefGoogle Scholar
  • 53 Fachinformation. Tecfidera®. April 2014.
    Google Scholar
  • 54 Gold R, Phillips JT, Havrdova E et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. 66th Annual Meeting of the American Academy of Neurology April 30, Philadelphia, Pennsylvania; 2014.
    Google Scholar
  • 55 http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf
  • 56 Fachinformation. AUBAGIO® 14 mg Filmtabletten. November 2013.
    Google Scholar
  • 57 Chambers CD, Johnson DL, Robinson LK et al. Organization of Teratology Information Specialists Collaborative Research Group. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum 2010; 62: 1494-1503
    CrossrefGoogle Scholar
  • 58 Cassina M, Johnson DL, Robinson LK et al. Organization of Teratology Information Specialists Collaborative Research Group. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum 2012; 64: 2085-2094
    CrossrefGoogle Scholar
  • 59 Fachinfo. Lemtrada® 12 mg Konzentrat zur Herstellung einer Infusionslo¨sung. Dezember 2013.
    Google Scholar
  • 60 Carp HJ, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun 2012; 38: 266-274
    CrossrefGoogle Scholar
  • 61 De Santis M, Straface G, Cavaliere AF et al. The first case of mitoxantrone exposure in early pregnancy. Neurotoxicology 2007; 28: 696-697
    CrossrefGoogle Scholar
  • 62 Hellwig K, Schimrigk S, Chan A et al. A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis. J Neurol Sci 2011; 307: 164-165
    CrossrefGoogle Scholar
  • 63 Azuno Y, Kaku K, Fujita N. Mitoxantron and etoposid in breastmilk. Am J Hematol 1995; 48: 131-132
    Google Scholar
  • 64 Giacalone PL, Benos P, Rousseau O. Chemotherapy for breast carcinoma during pregnancy. Cancer 1999; 86: 2266-2272
    CrossrefGoogle Scholar
  • 65 Reynoso EE, Huerta F. Acute leukemia and pregnancy – fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol 1994; 33: 703-716
    CrossrefGoogle Scholar
  • 66 Cocco E, Sardu C, Gallo P et al. FEMIMS Group. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008; 14: 1225-1233
    CrossrefGoogle Scholar
  • 67 Blumenfeld Z, Shapiro D, Shteinberg M et al. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus 2000; 9: 401-405
    CrossrefGoogle Scholar
  • 68 Telez N, Gris J, Tintore M et al. Prevention of persistent ovarian failure after mitoxantrone in women with MS. Design of a treatment protocol with triptorelin. Multiple sclerosis 2006; 12 (Suppl. 01) P758
    Google Scholar
  • 69 Ericson A, Källén BA. Nonsteroidal anti-inflammatory drugs in early pregnancy. Reprod Toxicol 2001; 15: 371-375
    CrossrefGoogle Scholar
  • 70 Ratnayaka BD, Dhaliwal H, Watkin S. Neonatal convulsions after withdrawal of baclofen. Br Med J 2001; 323: 85
    Google Scholar
  • 71 Moran LR, Almeida PG, Worden S et al. Intrauterine baclofen exposure: a multidisciplinary approach. Pediatrics 2004; 114: e267-269
    CrossrefGoogle Scholar
  • 72 Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27: 993-1002
    CrossrefGoogle Scholar
  • 73 Vajda FJ, Hitchcock AA, Graham J et al. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51: 805-810
    CrossrefGoogle Scholar
  • 74 Cunnington MC, Weil JG, Messenheimer JA et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76: 1817-1823
    CrossrefGoogle Scholar
  • 75 Jentink J, Dolk H, Loane MA et al. EUROCAT Antiepileptic Study Working Group. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. Br Med J 2010; 341: c6581
    CrossrefGoogle Scholar
  • 76 Fujii H, Goel A, Bernard N et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 2013; 80: 1565-1570
    CrossrefGoogle Scholar
  • 77 Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-1733
    CrossrefGoogle Scholar
  • 78 Nordeng H, van Gelder MM, Spigset O et al. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32: 186-194
    CrossrefGoogle Scholar
  • 79 Colvin L, Slack-Smith L, Stanley FJ et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011; 91: 142-152
    CrossrefGoogle Scholar
  • 80 Merlob P, Birk E, Sirota L et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009; 85: 837-841
    CrossrefGoogle Scholar
  • 81 Hellwig KKM, Gold R, Langer-Gould A. Exclusive breastfeeding reduces the risk of postpartum relapses – a prospective study from the German MS and pregnancy registry: Experience from a nationwide database. Neurology 2011; 76: A272
    Google Scholar
  • 82 Langer-Gould A, Huang SM, Gupta R et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009; 66: 958-963
    CrossrefGoogle Scholar
  • 83 Portaccio E, Ghezzi A, Hakiki B et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology 2011; 77: 145-150
    CrossrefGoogle Scholar
  • 84 Airas L, Jalkanen A, Alanen A et al. Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis. Neurology 2010; 75: 474-476
    CrossrefGoogle Scholar
  • 85 Pakpoor J, Disanto G, Lacey MV et al. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol 2012; 259: 2246-2248
    CrossrefGoogle Scholar
  • 86 Greenberger PA, Odeh YK, Frederiksen MC et al. Pharmacokinetics of prednisolone transfer to breast milk. Clin Pharmacol Ther 1993; 53: 324-328
    CrossrefGoogle Scholar
  • 87 Kumar AR, Hale TW, Mock RE. Transfer of interferon alfa into human breast milk. J Hum Lact 2000; 16: 226-228
    CrossrefGoogle Scholar
  • 88 Hale TW, Siddiqui AA, Baker TE. Transfer of interferon β-1a into human breastmilk. Breastfeed Med 2012; 7: 123-125
    CrossrefGoogle Scholar
  • 89 de Seze J, Chapelotte M, Delalande S et al. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler 2004; 10: 596-597
    CrossrefGoogle Scholar
  • 90 Achiron A, Rotstein Z, Noy S et al. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J Neurol 1996; 243: 25-28
    Google Scholar
  • 91 Achiron A, Kishner I, Dolev M et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 2004; 251: 1133-1137
    Google Scholar
  • 92 Haas J, Hommes OR. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007; 13: 900-908
    CrossrefGoogle Scholar
  • 93 Portaccio E, Ghezzi A, Hakiki B et al. MS Study Group of the Italian Neurological Society. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry 2014; 85: 845-850
    CrossrefGoogle Scholar
  • 94 Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol 2010; 257: 580-583
    CrossrefGoogle Scholar
  • 95 Lu E, Zhu F, Zhao Y et al. Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult Scler 2014; 20: 1260-1264
    CrossrefGoogle Scholar
  • 96 Pecori C, Giannini M, Portaccio E et al. MS Study Group of the Italian Neurological Society. Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. BMC Neurol 2014; 14: 114
    CrossrefGoogle Scholar
  • 97 Hanulíková P, Vlk R, Meluzínová E et al. Pregnancy and multiple sclerosis – outcomes analysis 2003–2011. Ceska Gynekol 2013; 78: 142-148
    Google Scholar
  • 98 Hellwig K, Schimrigk S, Beste C et al. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol 2009; 61: 65-68
    CrossrefGoogle Scholar
  • 99 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000081/WC500053225.pdf
  • 100 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000102/WC500029425.pdf
  • 101 Fachinformation. Copaxone® 20 mg/ml. Mai 2014.
    Google Scholar
  • 102 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000603/WC500148205.pdf
  • 103 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf
  • 104 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002601/WC500162070.pdf
  • 105 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002514/WC500148684.pdf
  • 106 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003718/WC500150522.pdf
  • 107 Fachinformation. Ralenova® 2 mg/ml. Januar 2008.
    Google Scholar